These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 26115577)

  • 21. Novel lead structures for p38 MAP kinase via FieldScreen virtual screening.
    Cheeseright TJ; Holm M; Lehmann F; Luik S; Göttert M; Melville JL; Laufer S
    J Med Chem; 2009 Jul; 52(14):4200-9. PubMed ID: 19489590
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.
    Das J; Moquin RV; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2652-7. PubMed ID: 18359226
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis, and biological evaluation of phenylamino-substituted 6,11-dihydro-dibenzo[b,e]oxepin-11-ones and dibenzo[a,d]cycloheptan-5-ones: novel p38 MAP kinase inhibitors.
    Laufer SA; Ahrens GM; Karcher SC; Hering JS; Niess R
    J Med Chem; 2006 Dec; 49(26):7912-5. PubMed ID: 17181176
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Syntheses and structure-activity relationships for some triazolyl p38α MAPK inhibitors.
    Seerden JP; Leusink-Ionescu G; Leguijt R; Saccavini C; Gelens E; Dros B; Woudenberg-Vrenken T; Molema G; Kamps JA; Kellogg RM
    Bioorg Med Chem Lett; 2014 Mar; 24(5):1352-7. PubMed ID: 24508134
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimization of alpha-ketoamide based p38 inhibitors through modifications to the region that binds to the allosteric site.
    Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst JT; Gibbs A; Kahl J; Kessler L; Kucharski J; Lum C; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Urban J; Wang Z; Larson CJ
    Bioorg Med Chem Lett; 2010 Aug; 20(16):4819-24. PubMed ID: 20663667
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
    Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
    ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SAR of benzoylpyridines and benzophenones as p38alpha MAP kinase inhibitors with oral activity.
    Revesz L; Blum E; Di Padova FE; Buhl T; Feifel R; Gram H; Hiestand P; Manning U; Rucklin G
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3601-5. PubMed ID: 15177483
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity.
    Hill RJ; Dabbagh K; Phippard D; Li C; Suttmann RT; Welch M; Papp E; Song KW; Chang KC; Leaffer D; Kim YN; Roberts RT; Zabka TS; Aud D; Dal Porto J; Manning AM; Peng SL; Goldstein DM; Wong BR
    J Pharmacol Exp Ther; 2008 Dec; 327(3):610-9. PubMed ID: 18776065
    [TBL] [Abstract][Full Text] [Related]  

  • 29. From Enzyme to Whole Blood: Sequential Screening Procedure for Identification and Evaluation of p38 MAPK Inhibitors.
    Bauer SM; Kubiak JM; Rothbauer U; Laufer S
    Methods Mol Biol; 2016; 1360():123-48. PubMed ID: 26501907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Azastilbenes: a cut-off to p38 MAPK inhibitors.
    Poon JF; Alao JP; Sunnerhagen P; Dinér P
    Org Biomol Chem; 2013 Jul; 11(27):4526-36. PubMed ID: 23719673
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytokine regulation by MAPK activated kinase 2 in keratinocytes exposed to sulfur mustard.
    Yego EC; Dillman JF
    Toxicol In Vitro; 2013 Oct; 27(7):2067-75. PubMed ID: 23851002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Continued exploration of the triazolopyridine scaffold as a platform for p38 MAP kinase inhibition.
    Jerome KD; Rucker PV; Xing L; Shieh HS; Baldus JE; Selness SR; Letavic MA; Braganza JF; McClure KF
    Bioorg Med Chem Lett; 2010 Jan; 20(2):469-73. PubMed ID: 19969459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of N-substituted pyridinones as potent and selective inhibitors of p38 kinase.
    Selness SR; Devraj RV; Monahan JB; Boehm TL; Walker JK; Devadas B; Durley RC; Kurumbail R; Shieh H; Xing L; Hepperle M; Rucker PV; Jerome KD; Benson AG; Marrufo LD; Madsen HM; Hitchcock J; Owen TJ; Christie L; Promo MA; Hickory BS; Alvira E; Naing W; Blevis-Bal R
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5851-6. PubMed ID: 19751974
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis and biological testing of N-aminoimidazole-based p38alpha MAP kinase inhibitors.
    Bracht C; Hauser DR; Schattel V; Albrecht W; Laufer SA
    ChemMedChem; 2010 Jul; 5(7):1134-42. PubMed ID: 20473979
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DBM1285 suppresses tumor necrosis factor alpha production by blocking p38 mitogen-activated protein kinase/mitogen-activated protein kinase-activated protein kinase 2 signaling pathway.
    Kang JS; Kim HM; Choi IY; Han SB; Yoon YD; Lee H; Park KH; Cho IJ; Lee CW; Lee K; Lee KH; Park SK
    J Pharmacol Exp Ther; 2010 Aug; 334(2):657-64. PubMed ID: 20427474
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and biological activity of 2H-quinolizin-2-one based p38alpha MAP kinase inhibitors.
    Tynebor RM; Chen MH; Natarajan SR; O'Neill EA; Thompson JE; Fitzgerald CE; O'Keefe SJ; Doherty JB
    Bioorg Med Chem Lett; 2010 May; 20(9):2765-9. PubMed ID: 20378346
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure- and ligand-based drug design of novel p38-alpha MAPK inhibitors in the fight against the Alzheimer's disease.
    Pinsetta FR; Taft CA; de Paula da Silva CH
    J Biomol Struct Dyn; 2014; 32(7):1047-63. PubMed ID: 23805842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitors.
    Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst JT; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1772-7. PubMed ID: 18325768
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and structure-activity relationship of aminobenzophenones. A novel class of p38 MAP kinase inhibitors with high antiinflammatory activity.
    Ottosen ER; Sørensen MD; Björkling F; Skak-Nielsen T; Fjording MS; Aaes H; Binderup L
    J Med Chem; 2003 Dec; 46(26):5651-62. PubMed ID: 14667219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery and characterization of atropisomer PH-797804, a p38 MAP kinase inhibitor, as a clinical drug candidate.
    Xing L; Devadas B; Devraj RV; Selness SR; Shieh H; Walker JK; Mao M; Messing D; Samas B; Yang JZ; Anderson GD; Webb EG; Monahan JB
    ChemMedChem; 2012 Feb; 7(2):273-80. PubMed ID: 22174080
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.